MA29849B1 - Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine - Google Patents
Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecineInfo
- Publication number
- MA29849B1 MA29849B1 MA30812A MA30812A MA29849B1 MA 29849 B1 MA29849 B1 MA 29849B1 MA 30812 A MA30812 A MA 30812A MA 30812 A MA30812 A MA 30812A MA 29849 B1 MA29849 B1 MA 29849B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- medicine
- alkyl
- activity
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Composés ayant une activité au niveau du récepteur M1 et leurs utilisations en médecine Des composés qui présentent une activité au niveau du récepteur M1 et leurs utilisations en médecine. Il est proposé des composés de formule (I) et leurs sels et produits de solvatation : formule dans laquelle R4 représente un groupe fluoro, R5 est choisi entre un atome d'hydrogène et un atome d'halogène, des groupes cyano, alkyle en C1 à C6, alkyle en C1 à C6 substitué avec un ou plusieurs atomes de fluor, alkoxy en C1 à C6 et alkoxy en C1 à C6 substitué avec un ou plusieurs atomes de fluor ; et R6 est choisi entre un atome d'halogène, un groupe cyano, alkyle en C1 à C6, alkyle en C1 à C6 substitué avec un ou plusieurs atomes de fluor cycloalkyle en C3 à C6, cycloalkyle en C3 à C6 substitué avec un ou plusieurs atomes de fluor, alkoxy en C1 à C6 et alkoxy en C1 à C6 substitué avec un ou plusieurs atomes de fluor et Q représente un atome d'hydrogène ou un groupe alkyle en C1 à C6. Il est prévu que les composés soient utiles en thérapie, par exemple dans le traitement de troubles psychotiques et d'une altération cognitive.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0519950.0A GB0519950D0 (en) | 2005-09-30 | 2005-09-30 | Compounds |
GB0602040A GB0602040D0 (en) | 2006-02-01 | 2006-02-01 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29849B1 true MA29849B1 (fr) | 2008-10-03 |
Family
ID=37598231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30812A MA29849B1 (fr) | 2005-09-30 | 2008-04-04 | Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine |
Country Status (24)
Country | Link |
---|---|
US (2) | US8283364B2 (fr) |
EP (1) | EP1943230B1 (fr) |
JP (1) | JP5209480B2 (fr) |
KR (2) | KR20130091791A (fr) |
CN (1) | CN101321736B (fr) |
AR (1) | AR056103A1 (fr) |
AT (1) | ATE492537T1 (fr) |
AU (1) | AU2006296369B2 (fr) |
BR (1) | BRPI0616609A2 (fr) |
CA (1) | CA2624504C (fr) |
CR (1) | CR9904A (fr) |
DE (1) | DE602006019119D1 (fr) |
EA (1) | EA016286B1 (fr) |
IL (1) | IL190219A (fr) |
JO (1) | JO2634B1 (fr) |
MA (1) | MA29849B1 (fr) |
MY (1) | MY148504A (fr) |
NO (1) | NO20081945L (fr) |
NZ (1) | NZ566508A (fr) |
PE (1) | PE20070490A1 (fr) |
TW (1) | TWI389905B (fr) |
UA (1) | UA101299C2 (fr) |
WO (1) | WO2007036715A2 (fr) |
ZA (1) | ZA200802167B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288412B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
EP1937670A1 (fr) * | 2005-09-30 | 2008-07-02 | Glaxo Group Limited | Benzimidazolones exerçant une activite au niveau du recepteur m1 |
DE602006019119D1 (de) | 2005-09-30 | 2011-02-03 | Glaxo Group Ltd | Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin |
US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
GB0605785D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0718415D0 (en) | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
WO2009124882A1 (fr) * | 2008-04-09 | 2009-10-15 | H. Lundbeck A/S | Nouvelles pipéridinyl-1,3-dihydrobenzoimidazol-2-ones comme agonistes de m1 |
GB0817982D0 (en) | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
JP2017533227A (ja) * | 2014-11-03 | 2017-11-09 | ウィリアム・ボーモント・ホスピタルWilliam Beaumont Hospital | 低活動膀胱症候群を治療するための方法 |
JP6811187B2 (ja) * | 2015-04-29 | 2021-01-13 | ヤンセン ファーマシューティカ エヌ.ベー. | インドロン化合物、及びampa受容体調節因子としてのそれらの使用 |
EP4144736A1 (fr) | 2015-04-29 | 2023-03-08 | JANSSEN Pharmaceutica NV | Azabenzimidazoles et leur utilisation en tant que modulateurs des récepteurs ampa |
EP4019018A1 (fr) | 2015-09-11 | 2022-06-29 | Chase Pharmaceuticals Corporation | Combinaisons muscariniques et leur utilisation pour lutter contre des troubles hypocholinergiques du système nerveux central |
CN107673994A (zh) * | 2017-04-27 | 2018-02-09 | 联化科技股份有限公司 | 一种芳基甲烷类化合物的制备方法 |
CN107739342B (zh) * | 2017-11-29 | 2020-01-10 | 华南理工大学 | 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法 |
CN117049938B (zh) * | 2023-06-20 | 2024-06-14 | 山东轩德医药科技有限公司 | 一种6-溴-2,3-二氟甲苯的制备方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3161645A (en) * | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
US3989707A (en) * | 1974-06-21 | 1976-11-02 | Janssen Pharmaceutica N.V. | Benzimidazolinone derivatives |
US4292321A (en) | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
DE3124366A1 (de) | 1981-06-20 | 1982-12-30 | Hoechst Ag, 6000 Frankfurt | N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
JP3916093B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
EP0786997A4 (fr) * | 1994-10-27 | 1998-03-11 | Merck & Co Inc | Antagonistes de muscarine |
US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
US5574044A (en) | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
AU7478396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine agonists |
US5718912A (en) | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
DE60013464T2 (de) | 1999-10-13 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | Substituierte imidazolin-derivate |
SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
WO2001057019A1 (fr) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | INHIBITEURS INDALONE ET BENZIMIDAZOLONE DU FACTEUR Xa |
SI1975164T1 (sl) | 2001-04-18 | 2010-05-31 | Euro Celtique Sa | Oktahidrobenzimidazolonske spojine kot analgetiki |
EP1386920A4 (fr) | 2001-04-20 | 2005-09-14 | Banyu Pharma Co Ltd | Derives de benzimidazolone |
WO2004089942A2 (fr) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Derives de benzimidazolidinone utilises en tant qu'agents muscariniques |
US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
CA2457647A1 (fr) | 2001-10-02 | 2003-04-10 | Acadia Pharmaceuticals, Inc. | Derives de benzimidazolidinone utilises comme agents muscariniques |
WO2003037890A2 (fr) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
WO2003082333A1 (fr) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remede contre les troubles du sommeil |
US7279490B2 (en) | 2002-06-17 | 2007-10-09 | Merck & Co, Inc. | Ophthalmic compositions for treating ocular hypertension |
EP1569646A2 (fr) | 2002-12-13 | 2005-09-07 | Smithkline Beecham Corporation | Antagonistes de ccr5 utiles comme agents therapeutiques |
JP2005102133A (ja) | 2003-04-28 | 2005-04-14 | Ricoh Co Ltd | 画像形成装置及び宛先情報参照方法 |
WO2005009996A1 (fr) | 2003-07-23 | 2005-02-03 | Wyeth | Composes de sulfonyldihydrobenzimidazolone en tant que ligands de 5-hydroxytryptamine-6 |
PL1664036T3 (pl) | 2003-09-03 | 2012-04-30 | Pfizer | Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 |
JP2008518905A (ja) | 2004-11-02 | 2008-06-05 | ファイザー株式会社 | スルホニルベンゾイミダゾール誘導体 |
US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
EP1937670A1 (fr) | 2005-09-30 | 2008-07-02 | Glaxo Group Limited | Benzimidazolones exerçant une activite au niveau du recepteur m1 |
DE602006019119D1 (de) | 2005-09-30 | 2011-02-03 | Glaxo Group Ltd | Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin |
US8288412B2 (en) | 2005-09-30 | 2012-10-16 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
US8239995B2 (en) | 2006-09-08 | 2012-08-14 | The Gillette Company | Toothbrush with multiple bristles states |
GB0706189D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706187D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706167D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706174D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706173D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706165D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706188D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706164D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706170D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
GB0706190D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-09-27 DE DE602006019119T patent/DE602006019119D1/de active Active
- 2006-09-27 KR KR1020137020049A patent/KR20130091791A/ko not_active Application Discontinuation
- 2006-09-27 CA CA2624504A patent/CA2624504C/fr not_active Expired - Fee Related
- 2006-09-27 JP JP2008532866A patent/JP5209480B2/ja not_active Expired - Fee Related
- 2006-09-27 NZ NZ566508A patent/NZ566508A/en not_active IP Right Cessation
- 2006-09-27 EP EP06794584A patent/EP1943230B1/fr active Active
- 2006-09-27 EA EA200801001A patent/EA016286B1/ru not_active IP Right Cessation
- 2006-09-27 CN CN2006800451692A patent/CN101321736B/zh not_active Expired - Fee Related
- 2006-09-27 AU AU2006296369A patent/AU2006296369B2/en not_active Ceased
- 2006-09-27 BR BRPI0616609-1A patent/BRPI0616609A2/pt not_active IP Right Cessation
- 2006-09-27 WO PCT/GB2006/003590 patent/WO2007036715A2/fr active Application Filing
- 2006-09-27 UA UAA200803937A patent/UA101299C2/uk unknown
- 2006-09-27 AT AT06794584T patent/ATE492537T1/de not_active IP Right Cessation
- 2006-09-27 US US12/088,465 patent/US8283364B2/en not_active Expired - Fee Related
- 2006-09-27 KR KR1020087007797A patent/KR101374458B1/ko not_active IP Right Cessation
- 2006-09-27 MY MYPI20080901A patent/MY148504A/en unknown
- 2006-09-28 PE PE2006001183A patent/PE20070490A1/es not_active Application Discontinuation
- 2006-09-28 AR ARP060104268A patent/AR056103A1/es unknown
- 2006-09-28 JO JO2006342A patent/JO2634B1/en active
- 2006-09-28 TW TW095135887A patent/TWI389905B/zh not_active IP Right Cessation
-
2007
- 2007-09-10 US US11/852,455 patent/US8481566B2/en not_active Expired - Fee Related
-
2008
- 2008-03-17 IL IL190219A patent/IL190219A/en not_active IP Right Cessation
- 2008-04-04 MA MA30812A patent/MA29849B1/fr unknown
- 2008-04-18 CR CR9904A patent/CR9904A/es unknown
- 2008-04-23 NO NO20081945A patent/NO20081945L/no not_active Application Discontinuation
-
2009
- 2009-03-07 ZA ZA200802167A patent/ZA200802167B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29849B1 (fr) | Composes exercant une activite au niveau du recepteur m1 et leurs utilisations en medecine | |
CA2662848C (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique | |
RU2332212C2 (ru) | Аминоспирт | |
MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
MA28422B1 (fr) | Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1 | |
MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
CA2481461A1 (fr) | Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique | |
TNSN06358A1 (fr) | Methyl-aryl-ou-heteroaryl-amides substitues | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
TNSN07253A1 (fr) | Derives de n- (heteroaryl) -1h-indole-2-carboxamides et leur utilisation comme ligands du recepteur vanilloide trpv1 | |
MA31319B1 (fr) | Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
MA34551B1 (fr) | Agent de lutte contre des organismes nuisibles | |
TNSN06075A1 (fr) | Phenyl-ou pyridylamides servant d'antagonistes de la prostaglandine e2 | |
MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
MA28675B1 (fr) | Piperazinediones utilises en tant qu'antagonistes du recepteur de l'oxytocine | |
AR056943A1 (es) | DERIVADOS DE AMIDAS, ISoMEROS DE LOS MISMOS O LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS COMO EL ANTAGONISTA DEL RECEPTOR VANILOIDE Y LAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS MISMOS | |
TNSN05224A1 (fr) | Derives azabicycliques a substituants pyridyloxymethyle et benzisoxazole | |
MA33893B1 (fr) | Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique | |
TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
FR2856684A1 (fr) | Derives de diphenylpyridine, leur preparation et leur application en therapeutique | |
TN2011000550A1 (fr) | Derives de cyclopenta[c] pyrrolyla lkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
CA2171675A1 (fr) | Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations | |
MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
MA29559B1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |